Tables

Tables in the Text

Table 1           Big Pharma’s In-House and In-Licensed T-Cell and NK-Cell Engaging Bispecific Antibody Technologies

Table 2           Big Pharma’s Preferences for T-Cell and NK-Cell Engaging Bispecific Antibody Technologies

Table 3           Big Pharma’s Preferences for Half-Life Extension in T-Cell and NK Cell Engaging Bispecific Antibody Technologies

Table 4           Big Pharma’s Preferred Targets for T-Cell and NK Cell Engaging Bispecific Antibody Technologies

Table 5           Economic Terms of Big Pharma’s Collaboration & Licensing Agreements for T-Cell & NK Cell Engaging Bispecific Antibody Technologies

Table 6           Main Characteristics of Big Pharma’s T-cell Engaging Bispecific Antibody Technologies

Table 7           Safety and Effector Cell Features of Big Pharma’s T-cell Engaging Bispecific Antibody Technologies

Table 8           Overview of Applied Technology, Target and Highest R&D Phase of Big Pharma’s Proprietary T-cell and NK Cell Engaging Bispecific Antibodies

Table 9           Overview of Technology Companies with T-Cell and NK-Cell Engaging Bispecific Antibody Technologies

Table 10         Overview of Technology Companies for Safety Features and Mode of Cell Engagement of Ig-Based T-Cell or NK Cell Engaging Bispecific Technologies

Table 11         Overview of Targets and Highest R&D Phase of Ig-based T-Cell and NK Cell Engaging Antibodies from Technology Companies

Table 12         Overview of Partnering Deals of Technology Companies with Ig-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies

Table 13         Overview of Technology Companies for Safety Features and Mode of Cell Engagement of Fc-Based T-Cell or NK Cell Engaging Bispecific Technologies

Table 14         Overview of Targets and Highest R&D Phase of Fc-based T-Cell and NK Cell Engaging Antibodies from Technology Companies

Table 15         Overview of Partnering Deals of Technology Companies with Fc-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies

Table 16         Overview of Technology Companies for Safety Features and Mode of Cell Engagement of Binder-Based T-Cell or NK Cell Engaging Bispecific Technologies

Table 17         Overview of Targets and Highest R&D Phase of Binder-based T-Cell and NK Cell Engaging Antibodies from Technology Companies

Table 18         Overview of Partnering Deals of Technology Companies with Binder-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies

Table 19         Overview of Special Technology Companies for Safety Features and Mode of Cell Engagement of T-Cell or NK Cell Engaging Bispecific Technologies

Table 20         Overview of Targets and Highest R&D Phase of Various T-Cell and NK Cell Engaging Antibodies from Technology Companies

Table 21         Overview of Partnering Deals of Technology Companies with Various T-Cell and NK Cell Engaging Bispecific Antibody Technologies

Table 22         Overview of Drug Profiles for Drug Code, Target, Technology, Company, Indication and Highest R&D Phase

Table 23         Overview of Not Profiled Drug Candidates for Drug Code, Target, Technology, Company, Indication and Highest R&D Phase

Table 24         Tumor Target, Effector Cell Engagement, Tumor Type and Number of Bispecific Antibodies per Phase of T-Cell and NK Cell Engaging Bispecific Antibodies

Table 25         Pipeline of BCMA-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies

Table 26         Pipeline of CD33-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies

Table 27         Pipeline of CD20-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies

Table 28         Pipeline of CD123-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies

Table 29         Pipeline of PSMA-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies

Table 30         Financing Sources of Technology Companies with Bispecific T-Cell and NK Cell Engaging Antibody Technologies

Table 31         Amgen’s Bispecific T-Cell Engager Pipeline

Table 32         Celgene’s Clinical Pipeline of Bispecific T-Cell Redirecting Antibodies

Table 33         Janssen’s Clinical Pipeline of T-Cell Redirecting Bispecific Antibodies

Table 34         Pfizer’s T-cell Engaging Bispecific Antibody Pipeline

Table 35         Roche’s Pipeline of Clinical Stage T-Cell Redirecting Bispecific Antibodies

Table 36         Sanofi’s Bispecific T-Cell and NK Cell Engager Pipeline

Table 37         Abpro’s Pipeline of T-Cell Engaging TetraBi Antibodies

Table 38         Merus‘ Biclonics Development Pipeline

Table 39         Regeneron Pharmaceuticals T-Cell Engaging Bispecific Antibody Pipeline

Table 40         TeneoBio’s Pipeline of T-Cell Engaging Bi- and Multi-Specific Human Heavy Chain Antibodies

Table 41         YZY Biopharma‘s Pipeline of T-Cell Redirecting Bispecific Antibodies

Table 42         Partnering Terms for Zymeworks‘ Azymetric Technology

Table 43         Pipeline of ADAPTIR Molecules from Aptevo Therapeutics

Table 44         MacroGenics‘ Clinical Stage Pipeline of T-Cell Redirecting Bispecific DART Antibodies

Table 45         Xencor’s Bispecific T-Cell Engaging Antibody Pipeline

Table 46         Generon’s Pipeline of Bispecific ITab Antibodies

Table 47         Harpoon Therapeutics‘ TriTAC Pipeline

Table 48         Affimed Therapeutics‘ T-Cell and NK-Cell Engaging Antibody Pipeline

Table 49         GT Biopharma‘ Pipeline of Tri- and Tetra-Specific NK Cell Engagers

Table 50         Goals and Terms of Immunocore’s Industry Partnering Deals for ImmTAC Technology

Table 51         Immuncore’s Wholly Owned and Partnered Development Pipeline of ImmTACs

Table 52         Blincyto Global Sales

Table 53         Clinical Studies with IMCgp100